

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 January 2024 (11.01.2024)



(10) International Publication Number
WO 2024/008722 A2

(51) International Patent Classification:

C07D 487/04 (2006.01) C07D 487/10 (2006.01)
A61K 31/522 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/EP2023/068406

(22) International Filing Date:

04 July 2023 (04.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22182841.1	04 July 2022 (04.07.2022)	EP
22196374.7	19 September 2022 (19.09.2022)	EP
22211409.2	05 December 2022 (05.12.2022)	EP
22215488.2	21 December 2022 (21.12.2022)	EP
23154600.3	02 February 2023 (02.02.2023)	EP
23164257.0	27 March 2023 (27.03.2023)	EP
23169796.2	25 April 2023 (25.04.2023)	EP
23172505.2	10 May 2023 (10.05.2023)	EP

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **MUNA THERAPEUTICS APS** [DK/DK];
Ole Maaloes Vej 3, 2200 København N (DK).

(72) Inventors: **WHITLOCK, Gavin**; Sandexis Medicinal Chemistry Ltd, Innovation House, Discovery Park, Ramsgate Road, Sandwich Kent CT13 9FF (GB). **EMMERICH, Juliette**; Reitdiephaven 371, 9746 RG Groningen (NL). **MEISSNER, Johannes Wilhelm Georg**; Voetiusstraat 20, 9746 CB Groningen (NL). **BUSCH-PETERSEN, Jakob**; c/o Muna Therapeutics ApS, Ole Maaloes Vej 3, 2200 København N (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: TREM2 MODULATORS

(57) Abstract: The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as neurodegenerative diseases and to pharmaceutical compositions comprising the compounds.

WO 2024/008722 A2